Last Friday, Accentia Biopharmaceuticals, Inc (PINK:ABPI) started to climb up. Yesterday, the climb continued and ABPI added ABPI_chart1.pngthe next 23.08% to its price and traded over 313 thousand shares on the market. Quite an unusual gain, considering the fact that the stock has had negative price changes for two weeks. Apparently, something is happening with ABPI and traders are getting interested in it.

The most recent news on Accentia came up just yesterday, reporting that Biovest has issued a post-ASH update for the BiovaxID cancer vaccine and an Isotype Phase III overview. Besides, last week Accentia filed its 10-K report and announced an Antibody Manufacturing Contract, which additionally pumped up the stock price.

Following the records, we notice that the company has had another huge gain at the beginning of this month due to its agreement with Baxter Healthcare Corporation. However, the stock price fell down again shortly. It seems that the positive news couldn’t hold the up move for long.[BANNER]

Accentia_logo.gifAccentia Biopharmaceuticals, Inc. is a biotechnology company that is developing Revimmune as a system of care for the treatment of multiple sclerosis and other human autoimmune diseases. The company operates through its majority owned subsidiary Biovest International, Inc. According to its annual report, the company has a history of operating losses and the management expects to incur more losses in the future. For the fiscal year ended September 30 2010, ABPI reported a net loss of $47.8 million, negative cash flow from operating activities of $0.4 million and an aggregate accumulated deficit of $326 million.

The company’s profitability depends on its successful clinical trials, however, the continued operating losses would impair its ability to continue operations. In that case, Accentia will need substantial additional financing, which however could not be guaranteed.

Obviously, the only thing left for the company is to rely on its new manufacturing contract, while investors are waiting for the results of the shareholder meeting in January next year.